CRISPR-Cas13a-powered electrochemical biosensor for the detection of the L452R mutation in clinical samples of SARS-CoV-2 variants
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Since the end of 2019, a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has deprived numerous lives worldwide, called COVID-19. Up to date, omicron is the latest variant of concern, and BA.5 is replacing the BA.2 variant to become the main subtype rampaging worldwide. These subtypes harbor an L452R mutation, which increases their transmissibility among vaccinated people. Current methods for identifying SARS-CoV-2 variants are mainly based on polymerase chain reaction (PCR) followed by gene sequencing, making time-consuming processes and expensive instrumentation indispensable. In this study, we developed a rapid and ultrasensitive electrochemical biosensor to achieve the goals of high sensitivity, the ability of distinguishing the variants, and the direct detection of RNAs from viruses simultaneously. We used electrodes made of MXene-AuNP (gold nanoparticle) composites for improved sensitivity and the CRISPR/Cas13a system for high specificity in detecting the single-base L452R mutation in RNAs and clinical samples. Our biosensor will be an excellent supplement to the RT-qPCR method enabling the early diagnosis and quick distinguishment of SARS-CoV-2 Omicron BA.5 and BA.2 variants and more potential variants that might arise in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
Araf, Y., Akter, F., Tang, Y., Fatemi, R., Parvez, M. S. A., Zheng, C., & Hossain, M. G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27588 · Cited by 862
Self-citationQuantifying the risk of SARS‐CoV‐2 reinfection over time
O Murchu, E., Byrne, P., Carty, P. G., De Gascun, C., Keogan, M., O’Neill, M., Harrington, P., & Ryan, M. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2260 · Cited by 84
Cited by
Phototherapy in cancer treatment: strategies and challenges
Cai, Y., Chai, T., Nguyen, W., Liu, J., Xiao, E., Ran, X., Ran, Y., Du, D., Chen, W., & Chen, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02140-y · Cited by 453
Metadata
- Authors
- Chen, Z., Wu, C., Yuan, Y., Xie, Z., Li, T., Huang, H., Li, S., Deng, J., Lin, H., Shi, Z., Li, C., Hao, Y., Tang, Y., You, Y., Al-Hartomy, O. A., Wageh, S., Al-Sehemi, A. G., Lu, R., Zhang, L., Lin, X., He, Y., Zhao, G., Li, D., & Zhang, H.
- Venue
- Journal of Nanobiotechnology
- Published
- 2023-04-29
- Volume
- 21
- Issue
- 1
- Pages
- 141-141
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W4367368875
- Cited by
- 182
- References
- 4
- FWCI
- 33.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRISPR-Cas13a-powered electrochemical biosensor for the detection of the L452R mutation in clinical samples of SARS-CoV-2 variants. https://app.cochat.ai/papers/10.1186/s12951-023-01903-5
- The paper
- Chen, Z., Wu, C., Yuan, Y., Xie, Z., Li, T., Huang, H., Li, S., Deng, J., Lin, H., Shi, Z., Li, C., Hao, Y., Tang, Y., You, Y., Al-Hartomy, O. A., Wageh, S., Al-Sehemi, A. G., Lu, R., Zhang, L., . . . Zhang, H. (2023). CRISPR-Cas13a-powered electrochemical biosensor for the detection of the L452R mutation in clinical samples of SARS-CoV-2 variants. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-023-01903-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.